Heterozygous Familial Hypercholesterolemia (HeFH) Latest Advances

Little Evidence of Atherosclerosis in a Middle-Aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants Despite Elevated Lipoprotein(a) Levels.

Journal: Internal medicine (Tokyo, Japan)

Published: December 03, 2025

Life Course Approach to Familial Hypercholesterolemia.

Journal: Current cardiology reports

Published: November 12, 2025

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Journal: JAMA

Published: November 09, 2025

Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study.

Journal: JAMA

Published: November 09, 2025

Establishment of a human induced pluripotent stem cell line from a patient with familial hypercholesterolemia carrying a frameshift mutation in LDLR gene.

Journal: Stem cell research

Published: November 05, 2025

Genotype and phenotype of familial hypercholesterolemia in Egyptian children: a single-center study.

Journal: Journal of tropical pediatrics

Published: October 29, 2025

Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect-A Single-Center Study.

Journal: Journal of clinical medicine

Published: October 12, 2025

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report.

Journal: Journal of atherosclerosis and thrombosis

Published: October 08, 2025

Lipidomic Signature of Patients with Familial Hypercholesterolemia Carrying Pathogenic Variants Unveils a Cue of Increased Cardiovascular Risk.

Journal: International journal of molecular sciences

Published: September 27, 2025

Clinical features of familial hypercholesterolemia in children

Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics

Published: September 17, 2025

Massive Cutaneous Xanthomas and Critical Triple-Vessel Coronary Artery Disease From Familial Hypercholesterolemia in a 40-Year-Old Woman.

Journal: Cureus

Published: September 14, 2025

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia.

Journal: International journal of molecular sciences

Published: September 10, 2025

Filters

Little Evidence of Atherosclerosis in a Middle-Aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants Despite Elevated Lipoprotein(a) Levels.

Little Evidence of Atherosclerosis in a Middle-Aged Japanese Woman with Familial Hypercholesterolemia Carrying PCSK9 (p.Glu32Lys) and ABCG8 (p.Ile419Asn) Variants Despite Elevated Lipoprotein(a) Levels.

Life Course Approach to Familial Hypercholesterolemia.

Life Course Approach to Familial Hypercholesterolemia.

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial.

Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study.

Familial Hypercholesterolemia Screening in Childhood and Early Adulthood: A Cost-Effectiveness Study.

Establishment of a human induced pluripotent stem cell line from a patient with familial hypercholesterolemia carrying a frameshift mutation in LDLR gene.

Establishment of a human induced pluripotent stem cell line from a patient with familial hypercholesterolemia carrying a frameshift mutation in LDLR gene.

Genotype and phenotype of familial hypercholesterolemia in Egyptian children: a single-center study.

Genotype and phenotype of familial hypercholesterolemia in Egyptian children: a single-center study.

Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect-A Single-Center Study.

Diagnostic and Therapeutic Challenges of Homozygous and Severe Heterozygous Familial Hypercholesterolemia from Clinical Aspect-A Single-Center Study.

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report.

Evinacumab Improved the Homozygous Familial Hypercholesterolemia Lipid Metabolism: A Case Report.

Lipidomic Signature of Patients with Familial Hypercholesterolemia Carrying Pathogenic Variants Unveils a Cue of Increased Cardiovascular Risk.

Lipidomic Signature of Patients with Familial Hypercholesterolemia Carrying Pathogenic Variants Unveils a Cue of Increased Cardiovascular Risk.

Clinical features of familial hypercholesterolemia in children

Clinical features of familial hypercholesterolemia in children

Massive Cutaneous Xanthomas and Critical Triple-Vessel Coronary Artery Disease From Familial Hypercholesterolemia in a 40-Year-Old Woman.

Massive Cutaneous Xanthomas and Critical Triple-Vessel Coronary Artery Disease From Familial Hypercholesterolemia in a 40-Year-Old Woman.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia.

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor Therapy Reduces the Level of DNA Damage in Patients with Heterozygous Familial Hypercholesterolemia.